Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kent W Mouw

Showing results (91-100 of 121) with videos related to

Pageof 13
Sort By:
Advances in Radiation Oncology|June 14, 2017
Analysis of patient outcomes following proton radiation therapy for retinoblastomaKent W Mouw, Beow Y Yeap, Paul Caruso, et al.
Biorxiv : the Preprint Server for Biology|June 4, 2026
Genomic analysis of BCG unresponsive non-muscle-invasive bladder cancer identifies drivers of sensitivity to intravesical Gemcitabine/DocetaxelKendrick Yim, Matias Vergara, Jihyun Lee, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 18, 2016
Genomic Evolution after Chemoradiotherapy in Anal Squamous Cell CarcinomaKent W Mouw, James M Cleary, Brendan Reardon, et al.
The Journal of Clinical Investigation|September 23, 2021
RAF1 amplification drives a subset of bladder tumors and confers sensitivity to MAPK-directed therapeuticsRaie T Bekele, Amruta S Samant, Amin H Nassar, et al.
European Urology|February 27, 2018
Clinical and Genomic Characterization of Low-Prostate-specific Antigen, High-grade Prostate CancerBrandon A Mahal, David D Yang, Natalie Q Wang, et al.
Radiology|October 29, 2024
AI-derived Tumor Volume from Multiparametric MRI and Outcomes in Localized Prostate CancerDavid D Yang, Leslie K Lee, James M G Tsui, et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics|December 18, 2019
Prevalence of pathogenic germline cancer risk variants in high-risk urothelial carcinomaAmin H Nassar, Sarah Abou Alaiwi, Saud H AlDubayan, et al.
Molecular Cancer Research : MCR|February 24, 2026
Epigenetic Atlas of Bladder Cancer Reveals Master Transcription Factors and Risk-Associated Regulatory Elements in Luminal and Basal-Squamous Molecular SubtypesElio Adib, Amin H Nassar, Sarah Abou Alaiwi, et al.
British Journal of Cancer|December 21, 2019
A model combining clinical and genomic factors to predict response to PD-1/PD-L1 blockade in advanced urothelial carcinomaAmin H Nassar, Kent W Mouw, Opeyemi Jegede, et al.
JCO Precision Oncology|July 1, 2025
Relationship Among DNA Damage Response Gene Alterations, Molecular Subtypes, and Survival Outcomes in Patients With Metastatic Bladder Cancer Treated on CALGB 90601Gopa Iyer, Woonyoung Choi, Bin Luo, et al.
Pageof 13

Showing results (91-100 of 121) with videos related to

Sort By:
Pageof 13
Advances in Radiation Oncology|June 14, 2017
Analysis of patient outcomes following proton radiation therapy for retinoblastomaKent W Mouw, Beow Y Yeap, Paul Caruso, et al.
Biorxiv : the Preprint Server for Biology|June 4, 2026
Genomic analysis of BCG unresponsive non-muscle-invasive bladder cancer identifies drivers of sensitivity to intravesical Gemcitabine/DocetaxelKendrick Yim, Matias Vergara, Jihyun Lee, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 18, 2016
Genomic Evolution after Chemoradiotherapy in Anal Squamous Cell CarcinomaKent W Mouw, James M Cleary, Brendan Reardon, et al.
The Journal of Clinical Investigation|September 23, 2021
RAF1 amplification drives a subset of bladder tumors and confers sensitivity to MAPK-directed therapeuticsRaie T Bekele, Amruta S Samant, Amin H Nassar, et al.
European Urology|February 27, 2018
Clinical and Genomic Characterization of Low-Prostate-specific Antigen, High-grade Prostate CancerBrandon A Mahal, David D Yang, Natalie Q Wang, et al.
Radiology|October 29, 2024
AI-derived Tumor Volume from Multiparametric MRI and Outcomes in Localized Prostate CancerDavid D Yang, Leslie K Lee, James M G Tsui, et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics|December 18, 2019
Prevalence of pathogenic germline cancer risk variants in high-risk urothelial carcinomaAmin H Nassar, Sarah Abou Alaiwi, Saud H AlDubayan, et al.
Molecular Cancer Research : MCR|February 24, 2026
Epigenetic Atlas of Bladder Cancer Reveals Master Transcription Factors and Risk-Associated Regulatory Elements in Luminal and Basal-Squamous Molecular SubtypesElio Adib, Amin H Nassar, Sarah Abou Alaiwi, et al.
British Journal of Cancer|December 21, 2019
A model combining clinical and genomic factors to predict response to PD-1/PD-L1 blockade in advanced urothelial carcinomaAmin H Nassar, Kent W Mouw, Opeyemi Jegede, et al.
JCO Precision Oncology|July 1, 2025
Relationship Among DNA Damage Response Gene Alterations, Molecular Subtypes, and Survival Outcomes in Patients With Metastatic Bladder Cancer Treated on CALGB 90601Gopa Iyer, Woonyoung Choi, Bin Luo, et al.
Pageof 13